# Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

> **NCT02376972** · PHASE2 · TERMINATED · sponsor: **Alfasigma S.p.A.** · enrollment: 392 (actual)

## Conditions studied

- BACTERIAL VAGINOSIS

## Interventions

- **DRUG:** RIFAXIMIN VAGINAL TABLET 25 MG
- **DRUG:** RIFAXIMIN VAGINAL TABLET 100 MG
- **DRUG:** PLACEBO VAGINAL TABLET
- **DRUG:** METROGEL VAGINAL

## Key facts

- **NCT ID:** NCT02376972
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 392 (ACTUAL)
- **Why stopped:** According to the Recommendation of the Indipendent Data Monitoring Committee
- **Last updated:** 2016-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02376972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02376972, "Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02376972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*